An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Mutiforme

Grant

Date/time Interval

  • June 10, 2011 - December 31, 2014
  • Total Award Amount

  • 6000.00
  • Direct Costs

  • 4762.00
  • Sponsor Award Id

  • ABTC 0901
  • Contributor

  • Nabors M.D., Louis   Principal Investigator